<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724581</url>
  </required_header>
  <id_info>
    <org_study_id>2612-3681</org_study_id>
    <nct_id>NCT00724581</nct_id>
  </id_info>
  <brief_title>Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer</brief_title>
  <acronym>PASCART</acronym>
  <official_title>Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing lung resection due to pulmonary cancer can be compromised in their
      postoperative period due to atrial fibrillation.

      A retrospective analysis performed at our institution indicates that 30 % of the population
      develope atrial fibrillation in the postoperative period.

      Amiodarone is known to diminish the occurence of postoperative atrial fibrillation after
      heart surgery, why this drug is chosen as a prophylactic agent for the mentioned population.

      Amiodarone is administrated twice a day for 5 days at a dose of 600 mg oral treatment after
      an initial loading bolus og 300 mg intravenously.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Free of atrial fibrillation</measure>
    <time_frame>31082009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-benefit analysis of amiodarone prophylactic</measure>
    <time_frame>31082009</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resection of the lung due to confirmed diagnosis of cancer pulmones.

          -  Elective operation (scheduled operation for at least one day)

          -  Ready to be randomized

          -  Patient must be at least 18 at time of operation

        Exclusion Criteria:

          -  Former operation of the lung

          -  Former heart surgery

          -  Bradycardia below 40 beats/ min

          -  Hypotension with systolic blood pressure below 80 mmHg

          -  AV-blockage of any degree or sick sinus node

          -  QTc interval above 440 ms for men or above 460 ms for women

          -  Paroxysmal, persistent or permanent atrial fibrillation or flutter

          -  Former atrial fibrillation or flutter for more than a month.

          -  Pregnant or positive pregnancy test

          -  Breastfeeding

          -  ALAT of more than twice the normal over limit

          -  Treatment with monoamineoxidase inhibitors (MAOI)

          -  Allergy to one or more components in amiodarone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars R Zebis, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital Skejby</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars R Zebis, MD</last_name>
    <phone>+45 89495566</phone>
    <email>lrz@post.tele.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Decker, MD</last_name>
    <phone>+45 89495566</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars R Zebis, MD, Ph.D.</last_name>
      <phone>+45 89495566</phone>
      <email>lrz@post.tele.dk</email>
    </contact>
    <contact_backup>
      <last_name>Thomas D Christensen, MD, Ph.D.</last_name>
      <phone>+45 89495566</phone>
    </contact_backup>
    <investigator>
      <last_name>Lars R Zebis, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>July 28, 2008</last_update_submitted>
  <last_update_submitted_qc>July 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lars Riber Zebis</name_title>
    <organization>Aarhus University Hospital</organization>
  </responsible_party>
  <keyword>Atrial fibrillation, amiodarone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

